Athena Bitcoin Global — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Athena Bitcoin Global filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $234.60M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $285.39M | Mar 6, 2026 |
| FY2013 | Dec 31, 2013 | $0 | Mar 6, 2014 |
| FY2013 | Dec 31, 2012 | $0 | Mar 6, 2014 |
| FY2012 | Dec 31, 2011 | $0 | Feb 28, 2013 |
| FY2011 | Dec 31, 2010 | $0 | Mar 30, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.84M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $38.00M | Mar 6, 2026 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.03M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $10.28M | Mar 6, 2026 |
| FY2013 | Dec 31, 2013 | ($202.5K) | Mar 6, 2014 |
| FY2013 | Dec 31, 2012 | ($206.6K) | Mar 6, 2014 |
| FY2012 | Dec 31, 2011 | ($216.8K) | Feb 28, 2013 |
| FY2011 | Dec 31, 2010 | ($205.0K) | Mar 30, 2012 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.02M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $19.29M | Mar 6, 2026 |
| FY2013 | Dec 31, 2013 | ($96.8K) | Mar 6, 2014 |
| FY2013 | Dec 31, 2012 | ($109.9K) | Mar 6, 2014 |
| FY2012 | Dec 31, 2011 | ($118.5K) | Feb 28, 2013 |
| FY2011 | Dec 31, 2010 | ($119.7K) | Mar 30, 2012 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.55M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $1.35M | Mar 6, 2026 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.62M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $17.68M | Mar 6, 2026 |
| FY2013 | Dec 31, 2013 | ($18.2K) | Mar 6, 2014 |
| FY2013 | Dec 31, 2012 | ($14.9K) | Mar 6, 2014 |
| FY2012 | Dec 31, 2011 | ($20.9K) | Feb 28, 2013 |
| FY2011 | Dec 31, 2010 | ($24.3K) | Mar 30, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $69.47M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $78.03M | Mar 6, 2026 |
| FY2013 | Dec 31, 2013 | $0 | Mar 6, 2014 |
| FY2013 | Dec 31, 2012 | $0 | Mar 6, 2014 |
| FY2012 | Dec 31, 2011 | $17 | Feb 28, 2013 |
| FY2011 | Dec 31, 2010 | $27 | Mar 30, 2012 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.16M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $56.66M | Mar 6, 2026 |
| FY2013 | Dec 31, 2013 | $1.41M | Mar 6, 2014 |
| FY2013 | Dec 31, 2012 | $1.29M | Mar 6, 2014 |
| FY2012 | Dec 31, 2011 | $1.18M | Feb 28, 2013 |
| FY2011 | Dec 31, 2010 | $1.06M | Mar 30, 2012 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.31M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $21.37M | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | $11.02M | Mar 6, 2026 |
| FY2013 | Dec 31, 2013 | ($1.41M) | Mar 6, 2014 |
| FY2013 | Dec 31, 2012 | ($1.29M) | Mar 6, 2014 |
| FY2013 | Dec 31, 2011 | ($1.18M) | Mar 6, 2014 |
| FY2013 | Dec 31, 2010 | ($1.06M) | Mar 6, 2014 |
| FY2013 | Dec 31, 2009 | ($949.8K) | Mar 6, 2014 |
| FY2013 | Dec 31, 2008 | ($853.2K) | Mar 6, 2014 |
| FY2013 | Dec 31, 2007 | ($726.1K) | Mar 6, 2014 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($497.0K) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $5.54M | Mar 6, 2026 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.38M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $17.51M | Mar 6, 2026 |
| FY2011 | Dec 31, 2011 | $17 | Mar 30, 2012 |
| FY2011 | Dec 31, 2010 | $27 | Mar 30, 2012 |
| FY2011 | Dec 31, 2009 | $115 | Mar 30, 2012 |
| FY2011 | Dec 22, 1991 | $0 | Mar 30, 2012 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.37M | Mar 6, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 6, 2026 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 6, 2026 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4.10B | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | 4.10B | Mar 6, 2026 |
| FY2013 | Dec 31, 2013 | 15.23M | Mar 6, 2014 |
| FY2013 | Dec 31, 2012 | 15.23M | Mar 6, 2014 |
| FY2012 | Dec 31, 2011 | 1.52M | Feb 28, 2013 |
| FY2011 | Dec 31, 2010 | 1.52M | Mar 30, 2012 |